【摘要】 目的:探讨罗格列酮对空腹血糖正常的代谢综合征(MS)的急性冠脉综合征(ACS)患者体内部分炎症水平的影响。方法:30例合并空腹血糖正常的MS的ACS患者,随机被分为对照组(A组,按常规治疗)和罗格列酮组(B组,常规治疗+罗格列酮治疗),疗程均为4周。治疗前、后分别测定空腹血糖,血清总胆固醇(TC),低密度脂蛋白-胆固醇(LDL-C),高敏C反应蛋白(hs-CRP),肿瘤坏死因子α(TNF-α)和白介素6(IL-6)水平。结果:治疗4周后,治疗组空腹血糖,空腹胰岛素,血清hs-CRP、TNF-α水平均明显降低(P<0.05~<0.01),且较对照组更显著(P<0.05~<0.01)。结论:罗格列酮可减少粥样硬化斑块炎症反应,使合并空腹血糖正常的代谢综合征的急性冠脉综合征患者受益。更多还原

【Abstract】 Objective:To evaluate the therapeutic efficacy on inflammatory indexes in patients with acute coronary syndrome(ACS) and metabolic syndrome(MS) followed normal fasting blood glucose.Methods:A total of 30 ACS patients with MS followed normal fasting blood glucose were divided into two groups randomly: control group(group A,received routine therapy) and rosiglitazone therapy group(group B,received rosiglitazone 4mg daily on routine therapy).Therapeutic course was 4 weeks.The serum levels of fasting blood glucose(FBG)、total cholesterol(TC)、low density lipoprotein-cholesterol(LDL-C) and high sensitive C-reactive protein(hs-CRP)、tumor necrosis factor(TNF)-α、interlendin(IL)-6 were detected before and after therapy.Results:Four weeks later,the levels of FBG,FINS,IR,hs-CRP and TNF-α decreased significantly and more than those of control group(P<0.05~<0.01).Conclusion:Rosiglitazone can decrease inflammatory reaction in patients with metabolic syndrome followed normal fasting blood glucose.更多还原